+44(0)845 5195091


> technology

> contact us


Activiomics's core technology is TIQUAS or (Targeted Quantification of Cell Signalling).

TIQUAS quantifies global kinase activity without the need for labeling or antibody isolation. Unlike other phosphoproteomics techniques, TIQUAS can comprehensively profile and cross-compare phosphopeptides, ensuring accurate and reproducible data.

Activiomics technology works by using a protease to break down a cell or tissue extract into peptide fragments. Phosphopeptide enrichment, mass spectrometry and our proprietary TIQUAS software allow thousands of phosphopeptides to be quantified. Cross-comparison of treated samples enables biomarker discovery and/or drug profiling.

TIQUAS has broad application in the area of biomarker and drug discovery.

Biomarkers and Stratified Medicine

Stratified medicine refers to the careful selection of patients for the optimal delivery of treatments. It does this by using diagnostic biomarkers to predict which individuals with a disease are most likely to respond to a particular drug. The stratification of patients using biomarkers is key to reducing the administration of unnecessary (and often toxic) treatments, in reducing the incidence of adverse reactions to drugs and in reducing the enormous wastage associated with patients receiving ineffectual treatments.

Increasingly, pharmaceutical companies are turning to stratified medicine approaches during the clinical development of new drugs in order to increase the incidence of positive clinical outcomes and enhance the rate at which their drugs are approved by regulatory bodies. Indeed, the FDA issued a Draft Guidance document in July 2011 in which it states that companion diagnostics must identify patients more accurately for regulatory approval of new drugs.

To date, stratified medicine approaches have largely involved genetic screening to identify specific genes that correlate with disease prognosis or with drug responses. Often these approaches suffer from a lack of precision due to the lack of a direct connection between genetic characteristics and the biology of disease.

Activiomics has developed a powerful method for measuring the phosphorylation events that occur within cells and tissues that are a direct result of disease progression or the administration of drugs. Because phosphorylation events directly underpin the biology associated with disease progression/drug responses, phosphorylated proteins represent molecular targets that offer much more precise biomarker candidates than have hitherto been utilised.

© Activiomics Ltd 2013 All rights reserved | terms & conditions

site design by Freelance Creative Agency